Zenodo · Apr 9, 2026
NANO-APROS-V1.0
By yünlü ME
NANO-APROS V2.0 – 7-Layer Smart Nanoparticle System (Defensive Publication / Prior Art) Published by: Muzaffer Enes Yünlü DOI: 10.5281/zenodo.19572973 License: CC BY-NC-SA 4.0 Legal status: Publicly available technical document – constitutes prior art under patent law --- What is this document? This document describes a smart nanoparticle architecture combining four independent systems into a single nanoscale particle: · Targeting Matrix (APROS) · Logic Circuit (SYBEL-KRONOS) · Therapeutic Cargo (ENESPROTEJENİ) · Safety Layer (Kill-switch) Purpose: To prevent others from patenting these specific nanoparticle configurations and keep them in the public domain. --- Scope – 7-Layer Nanoparticle Architecture Layer Material (example) Function 1. Core PLGA / Liposome / SiO₂ Drug, mRNA, CRISPR cargo 2. Logic Circuit DNA origami + SYBEL-KRONOS Compute biomarkers, decide 3. Targeting Antibody / peptide / aptamer Tissue recognition 4. Negative Selection Anti-adressing ligands Block entry to healthy tissue 5. Sensor Layer pH, ROS, ATP sensors Measure biomarkers 6. Kill-Switch Degron + miRNA + CRISPRi Destroy on error 7. Coating PEG Increase circulation time Size: 50-200 nm (only this range defined) --- Concrete Measurement Methods Biomarker Method Catalog pH BCECF-AM fluorescent dye Thermo Fisher B1170 ROS (H₂O₂) Amplex Red Thermo Fisher A12222 ATP Luciferin-luciferase PerkinElmer 6016941 IL-6 / CRP / TGF-β / HBsAg ELISA R&D Systems / Bio-Rad Glucose Fluorescent sensor Abbott Freestyle --- Concrete Examples (8 Total) – Core of Prior Art # Disease Material Targeting Sensors Drugs 1 Pancreatic Cancer PLGA, 120 nm anti-EGFR + anti-PD-L1 pH < 6.5, ROS > 50 μM Paclitaxel + Navitoclax 2 Alzheimer's Liposome, 90 nm anti-amyloid-β + TfR ATP < 1 mM, pH < 7.0 NAD+ + Urolithin A + OSKM 3 Rheumatoid Arthritis SiO₂, 150 nm anti-CD20 + anti-TNFα IL-6 > 10 pg/mL, ROS > 40 μM Methotrexate + Dexamethasone 4 Hepatitis B Liposome, 80 nm anti-HBsAg HBsAg > 100 IU/mL Tenofovir + siRNA 5 Type 2 Diabetes PLGA, 130 nm anti-GLP1R Glucose > 200 mg/dL, ATP < 0.5 mM Metformin + FGF21 6 Heart Attack Liposome, 100 nm anti-cardiac troponin I pH < 6.8, ROS > 60 μM PARP activator + NAD+ 7 COVID-19 Liposome, 70 nm anti-ACE2 + anti-spike IL-6 > 40 pg/mL, CRP > 50 mg/L Remdesivir + Dexamethasone 8 Liver Fibrosis SiO₂, 140 nm anti-HSC TGF-β > 20 ng/mL Navitoclax --- Intervention Phases (F0–F5) with Concrete Durations Phase Function Concrete Durations (hours) F0 Diagnostic Mapping 1, 2, 4, 6, 8, 12, 24 F1 Targeted Killing 24, 48, 72 F2 Epigenetic Reset 48, 72, 96, 120, 144, 168 F3 DNA/Organelle Repair 24, 48, 72, 96, 120 F4 Metabolic Energy 24, 48, 72, 96 F5 Immune/Tissue Regeneration 48, 72, 96, 120, 144, 168 · Mandatory washout: 24 hours · Post-cycle rest: 48, 72, 96, 120, 144, 168 hours --- Kill-Switch (4 Layers) # Mechanism Trigger 1 Degron (FKBP12-F36V + dTAG-13) Time > 336 hours 2 Tissue-specific miRNA Wrong tissue (miR-122/1/124/142) 3 CRISPRi (dCAS9-KRAB) Unwanted expression 4 Intracellular sensor p53 > λ1, ROS > λ2, ATP < λ3 Condition: ANY trigger TRUE → particle destroyed, apoptosis initiated --- Negative Selection Ligands (Anti-Addressing) – 8 Examples Off-Target Tissue Negative Ligand Mechanism Non-liver GalNAc-ASGPR antagonist Receptor blockade Non-muscle Myomaker inhibitor peptide Fusion block Non-neural L1CAM-blocking nanobody Internalization block Non-endothelial Claudin-5 antagonist peptide Tight junction block Non-immune CD47-activating peptide Phagocytosis trigger Non-tumor Phosphatidylserine masker "Don't eat me" signal Non-pancreatic β GLP-1R blocking peptide Receptor blockade Non-cardiomyocyte Cav3 antagonist Calcium channel block --- What is covered as prior art? · The 8 examples + 7-layer architecture + 4 kill-switch layers + 8 negative ligands above · Obvious variations (under KSR v. Teleflex, 2007): · Material substitution (PLGA ↔ Liposome ↔ SiO₂) · Routine optimization of sensor thresholds · ±20% dose changes · Similar adjustment of phase durations and sequences --- What is NOT covered? · Diseases other than the 8 examples · Different numbers of layers (3, 5, 6 layers, etc.) · Particle sizes below 50 nm or above 200 nm · All 120 phase permutations (only those in examples) · Any efficacy claims (only "how to use" is defined) --- Who is this for? · Patent offices (prior art search) · Nanotechnology researchers, bioengineers, molecular biologists · Smart drug delivery companies · Open science advocates --- How to cite? Yünlü, M. E. (2026). NANO-APROS V2.0: Defensive Publication and Prior Art Document – 7-Layer Smart Nanoparticle System. Zenodo. https://doi.org/10.5281/zenodo.19572973 (Original concept: April 9, 2026; this version: April 14, 2026) --- Not / Note: Bu dokümanda tanımlanmayan hiçbir şey için prior art iddiasında bulunulmaz. No prior art is claimed for anything not explicitly defined in this document.